APA (7th ed.) Citation

A, N., & Z, C. (2025). In rifampicin-resistant TB, bedaquiline-containing regimens reduced unfavorable status vs. a control regimen at 132 wk. Annals of internal medicine, 178(2), JC19. https://doi.org/10.7326/ANNALS-24-03918-JC

Chicago Style (17th ed.) Citation

A, Nachman, and Chagla Z. "In Rifampicin-resistant TB, Bedaquiline-containing Regimens Reduced Unfavorable Status Vs. a Control Regimen at 132 Wk." Annals of Internal Medicine 178, no. 2 (2025): JC19. https://doi.org/10.7326/ANNALS-24-03918-JC.

MLA (9th ed.) Citation

A, Nachman, and Chagla Z. "In Rifampicin-resistant TB, Bedaquiline-containing Regimens Reduced Unfavorable Status Vs. a Control Regimen at 132 Wk." Annals of Internal Medicine, vol. 178, no. 2, 2025, p. JC19, https://doi.org/10.7326/ANNALS-24-03918-JC.